secwatch.observer — SEC 8-K summary
======================================

Issuer:     SANGAMO THERAPEUTICS, INC (SGMO)
CIK:        0001001233
Form:       8-K
Filed at:   2026-05-14T20:02:06+00:00
Accession:  0001628280-26-035061
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sangamo Q1 net loss $31M; cash only into Q3 2026; stock delisted to OTCQB
-------------------------------------------------------------------------

- Q1 2026 net loss $31.0M ($0.08/share) vs $30.6M loss in Q1 2025; revenue dropped to $1.4M from $6.4M.
- Cash and cash equivalents $27.6M as of March 31 – expects to fund operations only into Q3 2026.
- Common stock delisted from Nasdaq, now trading on OTCQB; hearing to appeal delisting scheduled June 9.
- Rolling BLA for Fabry gene therapy ST-920 underway; CMC module completion expected summer 2026 subject to funding.
- 2026 GAAP operating expense guidance $110M-$130M; company warns guidance depends on securing additional funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001233/000162828026035061/0001628280-26-035061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001233/000162828026035061/sgmo-20260514.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-035061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer